Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TVF Communications

- PMLiVE

Academics and industry collaborate to advance precision therapy in breast cancer

The AI-based clinical study is funded by a grant worth almost £800,000 from Innovate UK

Top-5 Trends in Virtual KOL Engagement

Register now for one of our upcoming webinars (February 26-28)

Impetus Digital

- PMLiVE

Regenxbio’s investigational gene therapy shows promise in Hunter syndrome

The rare genetic disease is estimated to affect one in every 100,000 to 170,000 births

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine available to buy in UK following MHRA endorsement

The XBB.1.5-adapted vaccine will be available for purchase from March 2024

- PMLiVE

UKRI announces £80m investment into new UK research hubs for AI research

The nine hubs will help to evolve AI across applications, including healthcare treatments

- PMLiVE

Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Research Partnership

- PMLiVE

Medscape Education Leads the Industry into New Era of Precision Education with Guaranteed Impact

NEWARK, N.J., Feb. 8, 2024 /PRNewswire/ -- Medscape Education has just unveiled its pioneering approach to developing and delivering medical education designed to drive guaranteed reach, precision targeting, and impact during this...

Medscape Education Global

- PMLiVE

NICE recommends STADA and Calliditas’ Kinpeygo to treat rare kidney disease IgAN

Affecting approximately 14,000 in England, IgA nephropathy occurs when IgA accumulates in the kidneys, causing inflammation and scarring

- PMLiVE

Almirall and CRG partner to advance therapeutic approaches for atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Study finds doctors have difficulty diagnosing disease in images of darker skin

Researchers have found that AI could be used to more accurately diagnose these patients

- PMLiVE

Imagine More for the reporting of consensus programme outputs

The Bedrock team reflects on the latest published guidance in the development of consensus programmes

Bedrock Healthcare Communications

- PMLiVE

Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links